- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05944328
Effectiveness of an Intervention of Pharmacotherapeutic Plans to Reduce Medication-related Problems in Geriatric Residences (RG)
Effectiveness of a Structured Pharmaceutical Review Intervention of Pharmacotherapeutic Plans to Reduce Medication-related Problems in Geriatric Residences: a Quasi-experimental Pragmatic Assay
Background: Patients living in Geriatric Residences (RG) have increased aging, comorbidity, spending on health resources and mortality. High drug use is associated with an increased risk of falls, disability, and death. It is estimated that 20-50% of inappropriate medications are consumed in the elderly.
Hypothesis: A pharmaceutical intervention based on a clinical review of the pharmacotherapeutic plan of patients in RG will be useful in optimizing the prescription in terms of safety, reducing by 10% or more the inappropriate prescriptions.
Objectives: Evaluate the effectiveness of a structured pharmaceutical intervention based on the clinical review of the pharmacotherapeutic plan to improve its adequacy.
Decrease inadequate prescriptions in patients admitted to RG by 10%
Methodology: Pre-post, quasi-experimental intervention study with control group with prospective follow-up of a cohort of patients in RG. The intervention consists of the clinical review of the pharmacotherapeutic plan carried out by the pharmacist and subsequently agreed in the Pharmacotherapeutic Advisory Committee.
Determinations: The study variables will be evaluated at baseline and 3 months post-intervention. The primary variable is number of inappropriate prescriptions.
Statistical analysis: Percentage change will be measured before and after the intervention. Descriptive statistics will be performed for quantitative variables such as qualitative and comparison of means and proportions.
Expected results: Achieve a 10% decrease in inappropriate prescriptions
Applicability and Relevance: This study will expand the collaboration between the Pharmacy and Primary Care physicians, promoting the continuum of care, strengthening the safety culture, and improving prescribing habits.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tarragona, Spain, 43003
- Recruiting
- Cecilia Campabadal Prats
-
Contact:
- Cecília Campabadal Prats
- Phone Number: 679716123
- Email: cprats.tgn.ics@gencat.cat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 65 years or older
- Pharmacological treatment with at least one drug and for a period of more than three months
Exclusion Criteria:
- Individuals who at the time of the pharmaceutical review were in hospital
- Patients nearing the end of life
- Patients whose participation was considered by the doctor responsible to be potentially detrimental
- Patients not covered by the public healthcare or pharmacy system were excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control group
|
|
Experimental: intervention group
|
The intervention consisted of a systematic and structured review of patient pharmacotherapeutic treatment plans to identify problems or situations of risk related to pharmacological treatments and to propose changes or improvements to optimise them. phases: Individualised review of pharmacological treatment plans to detect drug-related problems: Indication, Appropriateness, Effectiveness, Safety When a drug-related problem was detected according to the above criteria, the pharmacist proposed an adjustment to the pharmacotherapeutic plan. The proposals could include: discontinuation of the drug, change of drug, change to a therapeutic equivalent, initiation of treatment, change of dosage, change of frequency or intensified monitoring. The proposals made by the pharmacist were assessed and agreed upon by a committee comprising the doctors responsible and the pharmacist. Thereafter, the consensual proposals for change were discussed with the patient. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug-related problems
Time Frame: Basal
|
Total count
|
Basal
|
Drug-related problems
Time Frame: Three months
|
Total count
|
Three months
|
Drug-related problems
Time Frame: Basal
|
average prm per patient
|
Basal
|
Drug-related problems
Time Frame: Three months
|
average prm per patient
|
Three months
|
Drug-related problems
Time Frame: Basal
|
% patients with prm
|
Basal
|
Drug-related problems
Time Frame: Three months
|
% patients with prm
|
Three months
|
Polymedication:
Time Frame: Basal
|
Average number of drugs
|
Basal
|
Polymedication:
Time Frame: Three months
|
Average number of drugs
|
Three months
|
Polymedication:
Time Frame: Basal
|
number of polymedicated patients (> 10 drugs)
|
Basal
|
Polymedication:
Time Frame: Three months
|
number of polymedicated patients (>10 drugs)
|
Three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sociodemographic variables
Time Frame: Basal
|
genre: female/male
|
Basal
|
Sociodemographic variables
Time Frame: Basal
|
median age
|
Basal
|
Sociodemographic variables
Time Frame: Basal
|
average months in the geriatric residence
|
Basal
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Basal
|
number of prm classified as indication
|
Basal
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Basal
|
number of prm classified as adequate
|
Basal
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Basal
|
number of prm classified as effectiveness
|
Basal
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Basal
|
number of prm classified as security
|
Basal
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Three months
|
number of prm classified as indication
|
Three months
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Three months
|
number of prm classified as adequate
|
Three months
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Three months
|
number of prm classified as effectiveness
|
Three months
|
Description and classification of the DRPs detected Description and classification of the DRPs detected
Time Frame: Three months
|
number of prm classified as security
|
Three months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 22/191-P
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polypharmacy
-
University of RochesterNational Institute on Aging (NIA)Active, not recruitingPolypharmacyUnited States
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Queen's University, BelfastBelfast Health and Social Care Trust; National University of Ireland, Galway... and other collaboratorsActive, not recruitingPolypharmacyIreland, United Kingdom
-
Tabula Rasa HealthCareEnrolling by invitationPolypharmacy | PharmacogenomicsUnited States
-
University of BernUniversity of Zurich; Swiss National Science Foundation; University of Basel; Utrecht...CompletedMultimorbidity | PolypharmacySwitzerland
-
Royal College of Surgeons, IrelandUniversity of Dublin, Trinity College; Health Service Executive, IrelandCompletedMultimorbidity | PolypharmacyIreland
-
Northwestern UniversityUniversity of California, Los Angeles; National Institute on Aging (NIA); University... and other collaboratorsEnrolling by invitationPolypharmacyUnited States
-
Northwestern UniversityGordon and Betty Moore Foundation; ACCESS Community Health Network; Walgreen Co.CompletedPolypharmacyUnited States
-
Fundacion Miguel ServetActive, not recruiting
Clinical Trials on systematic and structured review of patient pharmacotherapeutic treatment plans
-
University of BergenKing's College London; University of Oslo; Karolinska Institutet; The Research... and other collaboratorsCompleted
-
Dufresne, Craig, MD, PCRecruitingFreeman-Sheldon Syndrome | Whistling Face Syndrome | Freeman-Sheldon Syndrome Variant | Sheldon-Hall Syndrome | Gordon Syndrome | Arthrogryposis Distal Type 3 | Arthrogryposis Distal Type 1 | Freeman-Burian SyndromeUnited States
-
Freeman-Sheldon Research Group, Inc.TerminatedCraniofacial Abnormalities | Arthrogryposis | Freeman-Sheldon Syndrome | Arthrogryposis Distal Type 2A | Whistling Face Syndrome | Craniocarpotarsal Dysplasia | Craniocarpotarsal Dystrophy | Freeman-Sheldon Syndrome Variant | Sheldon-Hall Syndrome | Arthrogryposis Distal Type 2B | Gordon Syndrome | Arthrogryposis... and other conditionsUnited States
-
Rigshospitalet, DenmarkCompleted
-
Technical University of MunichBayer; Organon; Sanofi-Synthelabo; AOK Bayern; Ratiopharm GmbH; Berlin-Chemie Menarini and other collaboratorsTerminated
-
Universitätsklinikum Hamburg-EppendorfAlbertinen Krankenhaus gGmbH; Elbe Kliniken Stade-Buxtehude GmbH; Reha Centrum... and other collaboratorsCompleted
-
Centre Francois BaclesseFrench cancer Institute INCaRecruitingThyroid Cancer | Intermediate RiskFrance
-
Hospices Civils de LyonCompletedTransplantation OrganFrance
-
Mansoura UniversityRecruiting
-
Mayo ClinicNational Cancer Institute (NCI)CompletedClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive)... and other conditionsUnited States